Tandem L2 Fusion Vaccines for Prevention of Human Papillomavirus Infection

Abstract (Set) HPV infection causes 5% of human cancers worldwide. Prevention of HPV infection will eliminate HPV associated cancers and their precursors. However, current licensed vaccines are derived from Ll capsid protein and only target a subset of the oncogenic HPV types (and therefore Pap screening programs must remain in place). JHU scientists have identified a low cost approach to broadly prevent benign and oncogenic HPV infections and their sequelae based upon vaccination with polymeric L2 fusion proteins. This polymeric L2-based HPV vaccine is expressed as a single fusion protein to provide broad protection, whereas licensed Ll VLP-based vaccines induce type-restricted immunity. The L2-polymeric fusion can be produced in E. coli, or other vectors, at low cost. Description (Set) • Generate broadly protective vaccines against HPV -related disease.
• L2-polymeric fusion can be produced in E. coli, or other vectors, at low cost. Proposed Use (Set) A broadly protective vaccine against Human papillomavirus infection and any of its sequelae. HPV infections cause cancer, pre-malignant infections and benign infections, including cutaneous and genital warts.

Inventor(s): Roden, Richard B. S.

Type of Offer: Licensing



« More Medical Patents

---